Thynk Capital
Overview
Thynk Capital is a venture capital firm specializing in early-stage investments in Therapeutics, Healthcare, and Technology sectors . The firm focuses on companies dedicated to longevity and combating aging diseases, providing capital and critical value-added resources to optimize performance and increase enterprise value . Thynk Capital typically invests in Convertible Note, Seed, and Series A rounds, aiming to deliver above-market returns to its limited partners .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Elevian | Sep 2018 | Seed | - |
| Repair Biotechnologies | Jun 2023 | Series A | Co-investor |
| WinSanTor | Nov 2017 | VC Round | Co-investor |
| Viscient Bio Inc | Sep 2021 | Convertible Debt | Co-investor |
| Klotho Therapeutics, Inc. | Nov 2017 | Series A | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Thynk Capital based?
Thynk Capital is headquartered in Las Vegas, Nevada, United States.
When was Thynk Capital founded?
Thynk Capital was founded in 2003.
How many portfolio companies does Thynk Capital have?
Thynk Capital has 5 portfolio companies in Caplight's dataset.
What are some companies in Thynk Capital's portfolio?
Portfolio companies visible on Caplight include Elevian, Repair Biotechnologies, WinSanTor, Viscient Bio Inc, Klotho Therapeutics, Inc..
What was Thynk Capital's most recent investment shown here?
Thynk Capital's most recent investment in this portfolio sample was in Repair Biotechnologies in 2023.
What sectors does Thynk Capital focus on?
Thynk Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Thynk Capital focus on?
Thynk Capital typically invests at the Early stage.
What is Thynk Capital's AUM?
Thynk Capital's assets under management are estimated between $0.0 and $50.0M.